Immunomodulatory imide drugs (IMiDs) bind CRBN, a substrate receptor of the Cul4A E3 ligase complex, enabling the recruitment of neo-substrates, such as CK1α, and their degradation via the ubiquitin-proteasome system. Here, we report FAM83F as such a neosubstrate. The eight FAM83 proteins (A-H) interact with and regulate the subcellular distribution of CK1α. We demonstrate that IMiD-induced FAM83F degradation requires its association with CK1α. However, no other FAM83 protein is degraded by IMiDs. We have recently identified FAM83F as a mediator of the canonical Wnt signalling pathway. The IMiDinduced degradation of FAM83F attenuated Wnt signalling in colorectal cancer cells and removed CK1α from the plasma membrane, mirroring the phenotype...
Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase substrate receptor cereb...
Maintaining a healthy cellular environment requires the constant control of proteostasis. E3 ubiquit...
The von Hippel-Lindau (VHL) and cereblon (CRBN) proteins are substrate recognition subunits of two u...
Immunomodulatory imide drugs (IMiDs) bind CRBN, a substrate receptor of the Cul4A E3 ligase complex,...
Immunomodulatory drugs (IMiDs) are important for the treatment of multiple myeloma and myelodysplast...
Immunomodulators (IMiDs) are an effective class of drugs used to treat blood cancers. IMiDs are beli...
The function of the FAM83F protein, like the functions of many members of the FAM83 family, is poorl...
Proteolysis-targeting chimaeras (PROTACs) as well as molecular glues such as immunomodulatory drugs ...
Immunomodulatory drugs (IMiDs), including thalidomide derivatives such as lenalidomide and pomalidom...
Background: Thalidomide was first released as a sedative and anti-emetic by a German pharmaceutical ...
The discovery and implementation of immunomodulatory drugs (IMiD®s) has revolutionized the treatment...
Immunomodulatory (IMiD) agents like lenalidomide and pomalidomide induce the recruitment of IKZF1 an...
Thalidomide analogues (or immunomodulatory imide drugs, IMiDs) are cornerstones in the treatment of ...
Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase substrate receptor cereb...
Maintaining a healthy cellular environment requires the constant control of proteostasis. E3 ubiquit...
The von Hippel-Lindau (VHL) and cereblon (CRBN) proteins are substrate recognition subunits of two u...
Immunomodulatory imide drugs (IMiDs) bind CRBN, a substrate receptor of the Cul4A E3 ligase complex,...
Immunomodulatory drugs (IMiDs) are important for the treatment of multiple myeloma and myelodysplast...
Immunomodulators (IMiDs) are an effective class of drugs used to treat blood cancers. IMiDs are beli...
The function of the FAM83F protein, like the functions of many members of the FAM83 family, is poorl...
Proteolysis-targeting chimaeras (PROTACs) as well as molecular glues such as immunomodulatory drugs ...
Immunomodulatory drugs (IMiDs), including thalidomide derivatives such as lenalidomide and pomalidom...
Background: Thalidomide was first released as a sedative and anti-emetic by a German pharmaceutical ...
The discovery and implementation of immunomodulatory drugs (IMiD®s) has revolutionized the treatment...
Immunomodulatory (IMiD) agents like lenalidomide and pomalidomide induce the recruitment of IKZF1 an...
Thalidomide analogues (or immunomodulatory imide drugs, IMiDs) are cornerstones in the treatment of ...
Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase substrate receptor cereb...
Maintaining a healthy cellular environment requires the constant control of proteostasis. E3 ubiquit...
The von Hippel-Lindau (VHL) and cereblon (CRBN) proteins are substrate recognition subunits of two u...